Zydus to Acquire Assertio

Paul, Weiss is advising Zydus Lifesciences Limited, an India-based global life sciences company, its acquisition of a U.S.-based pharmaceutical company focused on specialty and supportive-care therapies, through a tender offer followed by a second-step merger. Under the terms of the deal, Zydus will make a tender offer to acquire all outstanding shares of Assertio common stock for $23.50 per share in cash for a total approximate equity value of $166.4 million on a fully-diluted basis, calculated using the treasury stock method. Following the successful completion of the tender offer, Zydus will acquire any remaining shares not tendered in the tender offer through a second-step merger at the same price per share. The transaction is expected to close in the second quarter of 2026, subject to customary closing conditions.

The Paul, Weiss team is led by corporate partners Chelsea Darnell and Krishna Veeraraghavan, and includes partner Patricia Vaz de Almeida; litigation partners Geoffrey Chepiga and John Carlin and counsel Audrey Paquet; intellectual property partner Jeffrey Osterman; antitrust partner Jesse Solomon; tax partner Brian Krause; and executive compensation partner Arian Mossanenzadeh.